Trial Profile
A phase 2 study of Velcade [bortezomib] in subjects with relapsed or refractory follicular B-cell lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2022
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 28 Mar 2022 This trial has been completed in Belgium (End Date: 18 April 2011), according to European Clinical Trials Database record.
- 02 Nov 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Feb 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.